Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Breast Neoplasms, Male × eribulin × 1 year × Clear all

Sponsor

Conditions

Breast Neoplasms 24 Triple Negative Breast Neoplasms 10 Sarcoma 5 Neoplasm Metastasis 5 Liposarcoma 3 Inflammatory Breast Neoplasms 3 Urinary Bladder Neoplasms 2 Leiomyosarcoma 2 Carcinoma, Transitional Cell 2 Uterine Cervical Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Refractory Solid Tumors 1 Recurrence 1 Ketosis 1 Histiocytoma, Malignant Fibrous 1 Hemangiosarcoma 1 Hemangioendothelioma, Epithelioid 1 HR+HER2- Breast Cancer 1 HER2-negative Metastatic Breast Cancer 1 HER2-low Breast Cancer 1 Fludzoparib" and Anti-angiogenic 1 Colorectal Neoplasms 1 Brest Cancer 1 Brain Neoplasms 1 Advanced Breast Cancer 1

Interventions

Taxes 4 Paclitaxel 3 Cyclophosphamide 3 exemestane 2 Tamoxifen 2 Leuprolide 2 Letrozole 2 Immunotherapy 2 Goserelin 2 Doxorubicin 2 Anastrozole 2 trastuzumab biosimilar HLX02 1 romidepsin 1 ribociclib 1 pegfilgrastim 1 entinostat 1 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1 abemaciclib 1 Vitamins 1 Trastuzumab 1 Psychiatric Rehabilitation 1 PF-05280014 1 Ontruzant 1 Omeprazole 1 Ogivri 1 Neoadjuvant Therapy 1 Mental Status and Dementia Tests 1 Lapatinib 1 Indomethacin 1 Immunoglobulin G 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡